Active Systemic Lupus Erythematosus
Active Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease where the immune system mistakenly attacks healthy tissues, leading to inflammation and damage in various parts of the body.
Systemic Lupus Erythematosus: Deucravacitinib Study
We are evaluating a new medication, deucravacitinib, for individuals with active systemic lupus erythematosus. The study aims to determine if it is more effective than a placebo in reducing disease symptoms and improving overall health.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have lupus (SLE) diagnosed at least 24 weeks ago?
- Are you currently taking medications for lupus, such as anti-malarial agents or immunosuppressants?
- Do you have severe kidney problems or severe neuropsychiatric issues related to lupus?
- Have you been diagnosed with any other major autoimmune diseases like multiple sclerosis or rheumatoid arthritis?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Medical Center Artmed Ltd.
Haskovo, Bulgaria
Acibadem City Clinic Diagnostic And Consultation Center Ltd.
Sofia, Bulgaria
Medical Center Excelsior OOD
Sofia, Bulgaria
Sponsor: Bristol-Myers Squibb Services Unlimited Company
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.